vs
Side-by-side financial comparison of POWER SOLUTIONS INTERNATIONAL, INC. (PSIX) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
POWER SOLUTIONS INTERNATIONAL, INC. is the larger business by last-quarter revenue ($191.2M vs $129.7M, roughly 1.5× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 32.5%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 41.7%).
Adani Energy Solutions Ltd, formerly known as Adani Transmission Ltd, is an electric power transmission and distribution company headquartered in Ahmedabad. As of April 2025, the company operates a cumulative transmission network of 26,696 circuit kilometers and is one of the largest private sector power transmission companies operating in India.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
PSIX vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $129.7M |
| Net Profit | $16.1M | — |
| Gross Margin | 21.9% | 98.0% |
| Operating Margin | 12.7% | -25.0% |
| Net Margin | 8.4% | — |
| Revenue YoY | 32.5% | 73.4% |
| Net Profit YoY | -31.0% | — |
| EPS (diluted) | $0.69 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $191.2M | $129.7M | ||
| Q3 25 | $203.8M | $164.9M | ||
| Q2 25 | $191.9M | $114.4M | ||
| Q1 25 | $135.4M | $81.7M | ||
| Q4 24 | $144.3M | $74.8M | ||
| Q3 24 | $125.8M | $62.9M | ||
| Q2 24 | $110.6M | $54.1M | ||
| Q1 24 | $95.2M | $41.4M |
| Q4 25 | $16.1M | — | ||
| Q3 25 | $27.6M | $25.7M | ||
| Q2 25 | $51.2M | $-12.8M | ||
| Q1 25 | $19.1M | $-41.2M | ||
| Q4 24 | $23.3M | — | ||
| Q3 24 | $17.3M | $-54.8M | ||
| Q2 24 | $21.5M | $-70.4M | ||
| Q1 24 | $7.1M | $-136.1M |
| Q4 25 | 21.9% | 98.0% | ||
| Q3 25 | 23.9% | 99.0% | ||
| Q2 25 | 28.2% | 98.7% | ||
| Q1 25 | 29.7% | 94.3% | ||
| Q4 24 | 29.9% | 96.6% | ||
| Q3 24 | 28.9% | 97.4% | ||
| Q2 24 | 31.8% | 96.2% | ||
| Q1 24 | 27.0% | 96.4% |
| Q4 25 | 12.7% | -25.0% | ||
| Q3 25 | 13.9% | 15.1% | ||
| Q2 25 | 16.9% | -11.1% | ||
| Q1 25 | 18.2% | -52.2% | ||
| Q4 24 | 17.5% | -81.2% | ||
| Q3 24 | 16.3% | -89.3% | ||
| Q2 24 | 22.9% | -125.1% | ||
| Q1 24 | 11.2% | -336.5% |
| Q4 25 | 8.4% | — | ||
| Q3 25 | 13.5% | 15.6% | ||
| Q2 25 | 26.7% | -11.1% | ||
| Q1 25 | 14.1% | -50.4% | ||
| Q4 24 | 16.1% | — | ||
| Q3 24 | 13.8% | -87.1% | ||
| Q2 24 | 19.5% | -130.1% | ||
| Q1 24 | 7.5% | -328.9% |
| Q4 25 | $0.69 | $0.04 | ||
| Q3 25 | $1.20 | $0.28 | ||
| Q2 25 | $2.22 | $-0.14 | ||
| Q1 25 | $0.83 | $-0.47 | ||
| Q4 24 | $1.01 | $-0.71 | ||
| Q3 24 | $0.75 | $-0.70 | ||
| Q2 24 | $0.94 | $-0.91 | ||
| Q1 24 | $0.31 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.3M | $93.0M |
| Total DebtLower is stronger | $96.6M | — |
| Stockholders' EquityBook value | $178.6M | $114.8M |
| Total Assets | $424.7M | $605.2M |
| Debt / EquityLower = less leverage | 0.54× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $41.3M | $93.0M | ||
| Q3 25 | $49.0M | $110.9M | ||
| Q2 25 | $49.5M | $75.2M | ||
| Q1 25 | $50.0M | $61.9M | ||
| Q4 24 | $55.3M | $58.5M | ||
| Q3 24 | $40.5M | $36.4M | ||
| Q2 24 | $28.8M | $32.3M | ||
| Q1 24 | $33.1M | $43.3M |
| Q4 25 | $96.6M | — | ||
| Q3 25 | $96.7M | — | ||
| Q2 25 | $1.8M | — | ||
| Q1 25 | $1.0M | — | ||
| Q4 24 | $184.0K | — | ||
| Q3 24 | $238.0K | — | ||
| Q2 24 | $292.0K | — | ||
| Q1 24 | $345.0K | — |
| Q4 25 | $178.6M | $114.8M | ||
| Q3 25 | $162.5M | $73.6M | ||
| Q2 25 | $135.7M | $32.7M | ||
| Q1 25 | $84.3M | $32.8M | ||
| Q4 24 | $65.3M | $59.1M | ||
| Q3 24 | $42.1M | $-30.5M | ||
| Q2 24 | $24.8M | $15.1M | ||
| Q1 24 | $3.2M | $74.1M |
| Q4 25 | $424.7M | $605.2M | ||
| Q3 25 | $458.9M | $538.6M | ||
| Q2 25 | $437.7M | $555.3M | ||
| Q1 25 | $372.7M | $548.8M | ||
| Q4 24 | $328.2M | $594.1M | ||
| Q3 24 | $339.1M | $504.4M | ||
| Q2 24 | $307.6M | $551.1M | ||
| Q1 24 | $286.8M | $663.5M |
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.60× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | 0.11× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.6M | $60.7M |
| Free Cash FlowOCF − Capex | $-7.6M | — |
| FCF MarginFCF / Revenue | -4.0% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -0.29× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.6M | $60.7M | ||
| Q3 25 | $3.3M | $14.3M | ||
| Q2 25 | $16.7M | $5.0M | ||
| Q1 25 | $8.8M | $-42.2M | ||
| Q4 24 | $32.7M | $-35.7M | ||
| Q3 24 | $12.6M | $-42.5M | ||
| Q2 24 | $1.5M | $-40.2M | ||
| Q1 24 | $15.6M | $-119.0M |
| Q4 25 | $-7.6M | — | ||
| Q3 25 | $1.7M | $14.2M | ||
| Q2 25 | $14.6M | — | ||
| Q1 25 | $5.4M | — | ||
| Q4 24 | $30.0M | — | ||
| Q3 24 | $12.1M | — | ||
| Q2 24 | $822.0K | $-40.3M | ||
| Q1 24 | $14.8M | — |
| Q4 25 | -4.0% | — | ||
| Q3 25 | 0.8% | 8.6% | ||
| Q2 25 | 7.6% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 20.8% | — | ||
| Q3 24 | 9.7% | — | ||
| Q2 24 | 0.7% | -74.5% | ||
| Q1 24 | 15.6% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.8% | 0.1% | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.5% | — | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | 0.3% | 0.0% | ||
| Q2 24 | 0.6% | 0.2% | ||
| Q1 24 | 0.9% | 0.0% |
| Q4 25 | -0.29× | — | ||
| Q3 25 | 0.12× | 0.56× | ||
| Q2 25 | 0.33× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 1.40× | — | ||
| Q3 24 | 0.73× | — | ||
| Q2 24 | 0.07× | — | ||
| Q1 24 | 2.20× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PSIX
| Energy End Market | $153.4M | 80% |
| Industrial End Market | $33.3M | 17% |
| Transportation End Market | $4.6M | 2% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
